21 / 24
Notes:
Volume 9, Issue 5 (Suppl)
J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
Cancer Stem Cells and Oncology Research 2017
June 26-28, 2017
Page 56
10
th
International Conference on
June 26-28, 2017 London, UK
CANCER STEM CELLS AND
ONCOLOGY RESEARCH
Identification of a novel target that regulates breast cancer stem cells
Monther Al-Alwan
King Faisal Specialist Hospital and Research Centre, Saudi Arabia
T
here have been significant advances in breast cancer treatment, which have been attributed to the use of targeted therapy in
combinationwith surgery and chemotherapy. However, the tumor-relatedmortality remained highmainly due to chemoresistance
resulting in relapse and metastasis. Chemoresistance is widely believed to be regulated by a small subpopulation of the tumor bulk
that possess stem cell-like features and thus are called cancer stem cells (CSCs). We have shown significant association between worse
clinical outcome in breast cancer patients, including metastasis and shorter survival, and expression of fascin, an actin-bundling
protein. Moreover, we have also reported that fascin is a critical mediator of breast CSCs and chemoresistance, via the activation of
focal adhesion kinase (FAK), which is known to directly bind members of the integrin adhesion molecules. Here we have used fascin
loss and gain of function approaches to examine if fascin influences integrin expression to regulate breast CSC function. Our results
have demonstrated that fascin expression in breast cancer cells is directly associated with increased expression of integrins including:
CD49a, CD49C, CD49f, CD29 and CD61. Fascin-mediated integrin expression on breast cancer cells enhances their adhesion,
chemoresistance and tumorsphere formation ability. This study supports a role for fascin in the maintenance of breast CSCs via the
regulation of integrin expression. The outcome of this study is expected to provide another evidence that fascin targeting may present
a new approach for optimal treatment of breast cancer from the root.
Biography
Monther Al-Alwan has completed his PhD in immunology from Dalhousie University and postdoctoral studies from University of Manitoba, Canada. He is a Scientist
at the stem cell and tissue re-engineering program (SCTRP) at King Faisal Specialist Hospital and Research Centre and Adjunct Associate Professor at AlFaisal
University, Riyadh, Saudi Arabia. Currently, he is actively involved in dissecting the molecular pathways that regulate the function of cancer stem cells and how
this is related to chemoresistance and metastasis. He has more than 22 peer-reviewed publications in reputed journals and has been serving as an Editorial Board
Member of various international journals.
MAlwan@kfshrc.edu.saMonther Al-Alwan, J Cancer Sci Ther 2017, 9:5(Suppl)
DOI: 10.4172/1948-5956-C1-102